(Total Views: 441)
Posted On: 08/25/2017 8:30:56 AM
Post# of 30066
wow. Those Zacks guys really know how to nail 'em.
Falling Earnings Estimates Signal Weakness Ahead for Adamas (ADMS)
August 21, 2017
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Adamas Pharmaceuticals, Inc. ADMS, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in ADMS.
Falling Earnings Estimates Signal Weakness Ahead for Adamas (ADMS)
August 21, 2017
Similar to wise buying decisions, exiting certain underperformers at the right time helps maximize portfolio returns. Selling off losers can be difficult, but if both the share price and estimates are falling, it could be time to get rid of the security before more losses hit your portfolio.
One such stock that you may want to consider dropping is Adamas Pharmaceuticals, Inc. ADMS, which has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year. A Zacks Rank #4 (Sell) further confirms weakness in ADMS.
(1)
(0)
